Kornimate/medical-research-clean huggingface dataset:
cognitive training in stroke rehabilitation

Conditions: Executive Dysfunction; Cognitive Impairment

Summary: this is a randomized, controlled pilot study to evaluate the efficacy of "ascend-i" (a strategy and computer-based intervention to enhance daily cognitive functioning after stroke - inpatient), an inpatient intervention that combines computer-based cognitive training and coaching of cognitive strategies to improve working memory (wm) and related executive functions in individuals with stroke. the investigators hypothesize that relative to an "enhanced usual care" control condition, ascend will be associated with improvements in wm. the investigators also hypothesize that measures of baseline brain connectivity (assessed via participants' routine clinical magnetic resonance imaging scans) will predict response to ascend-i.


Eligibility criteria:
inclusion criteria: 1. patient admitted for a stroke and accepted to acute inpatient rehabilitation at nyp-weill cornell. 2. age 30-89 3. english speaking 4. ability to comprehend sufficiently to participate in the treatment 5. mild-moderate cognitive impairment as determined by a standard of care cognitive screening tools administered by occupational therapists (e.g., montreal cognitive assessment, symbol-digit modalities test, or other clinical standard of care instrument). we will review subjects' most recent cognitive assessment administered by ot (occupational therapists) and available in the emr (electronic medical records) to determine eligibility. 6. willingness to participate in full study duration 7. physically able to operate a computer keyboard, tablet/ipad, and mouse. exclusion criteria: 1. history of other neurologic disorder (e.g., parkinson's disease, multiple sclerosis, alzheimer's disease, brain tumor). history of previous stroke(s) will not be exclusionary as long as the subject does not self-report having lasting/persistent cognitive impairment from the prior stroke. 2. history of severe mental illness (e.g., schizophrenia, psychosis) or substance use disorder, recent history (in the past year) of alcohol/substance use disorder or symptoms of psychosis. note that the presence of post-stroke depression will not be grounds for exclusion. 3. history of dementia 4. moderate-severe hemispatial neglect as determined by ot evaluation 5. any factor that in the investigator's opinion is likely to compromise the subject's ability to participate in the study, including evidence that the subject may not understand and/or adhere to study requirements
compassionate use of omegaven in children

Conditions: Total Parenteral Nutrition-induced Cholestasis; Cholestasis; Short Bowel Syndrome; Gastroschisis; Intestinal Atresia; Infant, Premature, Diseases; Cholestasis of Parenteral Nutrition

Summary: this is a single-assignment study to evaluate whether omegaven (iv fish oil) is effective at treating liver disease in children on long-term iv nutrition.

children up to 18 years of age, on parenteral nutrition, with a direct bilirubin level of 2 mg/dl or greater will be eligible to receive omegaven at a maximum dose of 1 g/kg/day. up to 200 children will be eligible for enrollment. direct bilirubin levels and other labs will be monitored as well as growth parameters.

Eligibility criteria:
inclusion criteria: * live in or temporarily relocate to oklahoma * age less than 18 years, both sexes, all races * have a direct bilirubin level of ≥2 mg/dl for two consecutive weeks after at least 14 days of parenteral nutrition * received parenteral lipids at a maximum dose of 1.7 g/kg/day (24 g/kg over the two weeks prior) * are not currently enrolled in another lipid emulsion study exclusion criteria: * known food allergy to fish * known metabolic disorder of lipid metabolism * active coagulopathies (active bleeding or requiring blood product treatment in the prior 48 hours) * medical condition likely to result in death in the next 30 days

Keywords: fat emulsions, intravenous parenteral-nutrition-associated liver disease cholestasis omegaven fish oil
betty: benign prostatic hyperplasia transperineal targeted microwave therapy

Conditions: Prostate Hyperplasia

Summary: this is a pilot study on applying 3d-ultrasound-guided transperineal microwave needle ablation for men with symptomatic benign prostatic hyperplasia (bph).

this is a prospective, single centre, open-label and non-comparative trial planned on 12 patients. patients who fit inclusion criteria would be recruited and offered microwave ablation to the enlarged prostate. the patients will be closely followed up to 6 months after treatment with serial assessment on safety and efficacy.

Eligibility criteria:
inclusion criteria: * age over 50 years. * benign prostatic hyperplasia with prostate size 30-80 cc * ipss ≥ 14 * psa ≤ 4 ng/ml or psa \>4 ng/ml with no evidence of suspicious lesion on mpmri * maximum urine flow rate (qmax) ≤ 15 ml/s. * post-void residual ≤ 150 ml. * patient suitable for iv sedation and/or spinal anaesthesia and/or general anaesthesia and focal microwave ablation. * informed written consent exclusion criteria: * significant intravesical median lobe hyperplasia. * suspicious lesion on mpmri prostate * history of prostate, bladder or urethral surgery. * history of prostate cancer * presence of stones, bladder diverticulum and/or bladder tumor * history of long-term indwelling catheter. * urethral stricture * known coagulopathy or on anticoagulant * presence of a pacemaker. * active infection * dysuria due to bladder dysfunction. * serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to the screening visit. * neurological disorders that would impact bladder function (e.g., multiple sclerosis, parkinson's disease, spinal cord injury). * contraindications for mpmri exam or mr contrast * acute and/or chronic renal failure (gfr \ 1.5 mg/d). * patient currently participating in another interventional clinical trial.
to demonstrate the relative bioavailability of sandoz inc. and ucb pharma, inc (keppra) 750 mg levetiracetam tablets in healthy adults volunteers under fasting conditions

Conditions: Seizure

Summary: to demonstrate the relative bioavailability of sandoz inc. and ucb pharma, inc (keppra) 750 mg levetiracetam tablets in healthy adult volunteers under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.

Keywords: anticonvulsant
prevention of maternal hypotension during cesarean section with norepinephrine infusion.

Conditions: Hypotension; Obstetric Anesthesia Problems; Cesarean Section Complications; Hypotensive; Vasoconstriction

Summary: this will be a randomized study aiming at investigating the combination of a norepinephrine infusion and colloid preloading versus the combination of a norepinephrine infusion and crystalloid co-loading for the prevention of maternal hypotension during elective cesarean section

neuraxial techniques are the anesthetic techniques of choice in contemporary obstetric anesthesia practice, with a definitive superiority as compared to general anesthesia, since, by their use, serious complications involving the airway can be avoided.spinal anesthesia has become the favorable technique for both elective and emergency cesarean section due to a quick and predictable onset of action, however, it can be frequently complicated by hypotension, with incidence exceeding 80% occasionally. recently, noradrenaline has been shown to be effective in maintaining blood pressure in obstetric patients. another technique widely used to prevent hypotension is fluid administration. current evidence suggests that the combination of fluid administration and vasoconstrictive medications should be the main strategy for prevention and management of hypotension accompanying neuraxial anesthesia procedures during cesarean section. research is still underway in relation to the most appropriate timing for fluid administration, the most appropriate fluid volume as well as the type of fluid that should be administered. however, preloading of crystalloids seems to be inefficient as a sole strategy, while co-loading of colloids is more effective than co-loading of crystalloids for prevention of hypotension in the parturient. on the other hand, preloading and co-loading of colloids seem to be of equal effectiveness. literature is rather scarce regarding the comparison of colloid preloading and crystalloid co-loading. the aim of this randomized study will be to investigate the combination of a norepinephrine infusion and colloid preloading versus the combination of a norepinephrine infusion and crystalloid co-loading for the prevention of maternal hypotension during elective cesarean section.

Eligibility criteria:
inclusion criteria: * adult parturients, american society of anesthesiologists (asa) i-ii, * singleton gestation\>37 weeks * elective cesarean section exclusion criteria: * body mass index (bmi) \>40 kg/m2 * body weight \<50 kg * body weight\>100 kg * height\<150 cm * height\>180 cm * multiple gestation * fetal abnormality * fetal distress * active labor * cardiac disease * pregnancy-induced hypertension * thrombocytopenia * coagulation abnormalities * use of antihypertensive medication during pregnancy * communication or language barriers * lack of informed consent * contraindication for regional anesthesia
prevalence of gag reflex in healthy persons and across different patient groups and its relevance in dysphagia screening

Conditions: Neurological Diseases or Conditions

Summary: the aim of this study is to assess the prevalence of gag reflex in healthy young and healthy older subjects as well as in acute stroke patients, in patients with parkinsons´s disease, myasthenia gravis, multiple sclerosis and in geriatric patients.

in the clinical swallowing examination in acute stroke setting it is assumed that the absence of gag reflex is a predictor of aspiration risk. according to daniels et al. (1997) aspiration can be predicted with 96% sensitivity in case of absent or abnormal gag reflex. in clinical experience of investigators testing of gag reflex highly depends on patients´compliance and individual anatomical features such as mallampati score. furthermore, even if gag reflex is absent, swallowing does not have to be impaired. the presence of gag reflex in healthy cohorts and dysphagic patients has been examined in a few studies. davies et al. (1995) have shown that in 37% of healthy volunteers gag reflex was absent. ramsey et al. (2005) have shown that approx. 89% of the patients without gag reflex had dysphagia and 31% without dysphagia had a gag reflex. in both studies it was not stated to what extent the gag reflex could be examined in case of a high mallampati score. the present study aims at assessing the prevalence of gag reflex in healthy and neurological cohorts. the study protocol foresees testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluating present reactions. the mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher mallampati scores. all patients are tested once by one examiner.

Eligibility criteria:
inclusion criteria: * informed consent exclusion criteria: 1. healthy participants: neurological diseases pre-diagnosed dysphagia percutaneous endoscopic gastrostomy (peg) tube head and neck tumours chemo- and/or radiotherapy in the head and neck area reflux disease chronic obstructive pulmonary disease (copd) previous surgeries on the cervical spine or thyroid gland vocal cord paresis 2. geriatric patients neurologic diseases 3. stroke patients head and neck tumours chemo- and/or radiotherapy in the head and neck area reflux disease copd previous surgeries on the cervical spine or thyroid gland vocal cord paresis 4. neurologic patients without stroke head and neck tumours (except of intracranial tumors= chemo- and/or radiotherapy in the head and neck area reflux disease copd previous surgeries on the cervical spine or thyroid gland vocal cord paresis
dynamics of colonization and infection by multidrug-resistant pathogens in immunocompromised and critically ill patients

Conditions: Antimicrobial Drug Resistance; Antibiotic Resistant Infection; Clostridium Difficile; Carbapenem-Resistant Enterobacteriaceae Infection; Extended Spectrum Beta-Lactamase Producing Bacteria Infection; Vancomycin Resistant Enterococci Infection; Carbapenem Resistant Bacterial Infection; Vancomycin-Resistant Enterococcal Infection

Summary: the goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or decrease the risk of acquiring an infection or becoming colonized by pathogenic bacteria. participants will have the following samples collected during enrollment: stool samples (maximum 2x/week), blood draws (1x/week), oral swab (1x/week).

the objectives of this study are to dissect the main microbial, clinical, and antimicrobial resistance determinants that impact colonization and infection by vancomycin-resistant enterococci (vre), extended-spectrum beta-lactamase producing enterobacterales (esbl-e), carbapenem-resistant enterobacterales (cre), and clostridium difficile; to evaluate the role of commensal microbiota in vre, esbl-e/cre, and c. difficile colonization, and to define the functional aspects of keystone microbiota and mechanisms of protection against colonization/infection. patients will be recruited from both intensive care units (n=500) and stem cell transplant units (n=500) and will be followed until discharge from these units, or for a maximum of four weeks. in addition to stool, blood, and oral samples, enrolled patients will have clinical data collected by chart review to evaluate colonization/infection-related clinical status, microbiological laboratory information, exposure to antibiotics, and clinical outcomes. positive clinical cultures taken during the course of hospitalization will also be collected for analysis.

Eligibility criteria:
inclusion criteria: * admission to an intensive care unit or stem cell transplant unit (for allogeneic stem cell transplantation) within previous 24 hours exclusion criteria: * \<18 years of age * pregnancy * history of inflammatory bowel disease (crohn's disease, ulcerative colitis) * gastrointestinal derivation (colostomy, ileostomy, etc.)
evaluation of the accuracy of the elastic fusion mri-ultrasound obtained in vivo by the koelis™ system

Conditions: Cancer of the Prostate

Summary: the study aims at quantifying the registration error obtained in routine patients in different parts of the prostate and for operators with different experience in order to assess the average precision of the elastic mr-ultrasound fusion obtained by koelis™ system. patients referred for placement of intraprostatic fiducials before radiotherapy for prostate cancer will be prospectively offered to enter the study. the fiducials will be placed under transrectal ultrasound guidance, in the prostate apex, midgland and base, according to our routine procedure. a 3d ultrasound acquisition of the prostate will be obtained at the end of the placement. as per our routine procedure, patients will undergo unenhanced prostate mri to control the position of the fiducials. an elastic fusion of the mr images and the 3d ultrasound acquisitions will be retrospectively performed by operators of varying experience using the koelis system. the fiducials (visible on mr and ultrasound images) will be used to quantify the registration error.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient requiring placement of intraprostatic fiducials * no contra-indication for fiducials placement * no contra -indication to mri * no contra -indication for intravenous injection of gadolinium chelates * patient affiliated to the social security system * patients who received oral and written information exclusion criteria: * patient deprived of liberty as a result of a judicial or administrative decision. * patient under guardianship or curatorship. * any event preventing or prematurely interrupting the collection of assessment criteria would result in the premature exit of the subject.

Keywords: ultrasound koelis system mri gold grain
comparison of coronary ct angiography with conventional coronary angiography in liver and lung transplant candidates

Conditions: Coronary Artery Disease

Summary: the overall goal of this study is to determine if non-invasive imaging with state of the art ct coronary angiography can be used to screen for coronary artery disease in high risk patients prior to liver and lung transplantation. the current protocol for coronary artery disease assessment at ucsf before liver and lung transplantation involves screening with stress tests and/or coronary angiograms in patients with increased risk of coronary artery disease. coronary angiogram will be used as gold standard for assessment of coronary cta accuracy.


Eligibility criteria:
inclusion criteria: 1. liver transplant candidates referred for invasive coronary angiography which include: * patients with suspicious symptoms for cad or; * asymptomatic patients; * abnormal non-invasive testing or 1 major risk factor for coronary artery disease or lvef \< 60% on echo. 2. lung transplant candidates referred for invasive coronary angiography which include: * patients with suspicious symptoms for cad or; * asymptomatic patients; * abnormal non-invasive testing or 1 major risk factor for coronary artery disease or lvef \< 60% on echo in patients with low svr (typical for esld). 3. any ethnic background is acceptable. exclusion criteria: 1. patients with contraindications for the use of iodinated contrast (allergic reaction, renal failure, multiple myeloma, etc) will be excluded. 2. children and pregnant women will be excluded because of risks associated with radiation exposure. 3. patients must have no atrial fibrillation, as this will interfere with cardiac gating for the examination. 4. patients unable to give informed consent will be excluded as well.

Keywords: invasive coronary angiography multidetector coronary cta coronary artery disease detecting coronary artery disease
efficacy and safety of mirabegron in intracerebral hemorrhage

Conditions: Intracerebral Haemorrhage

Summary: intracerebral hemorrhage (ich) accounts for 10-15% of all strokes without effective pharmacological treatment. inflammation following ich contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (hspcs) are swiftly activated after ich. thereafter, these hspcs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. this study is to assess the safety and efficacy of a β3 adrenergic receptor agonist mirabegron as a potential treatment option in ich patients.

this study is to evaluate the efficacy and safety of mirabegron in patients with intracerebral hemorrhage based on standard therapy

Eligibility criteria:
inclusion criteria: 1. male or female patients aged above 18 years old. 2. the volume of the hematoma is 5-30 ml (including the cerebral cortex; putamen, thalamus, caudate nucleus and related deep tracts; cerebellar hemorrhage), which determined by ct scan. 3. the onset of cerebral hemorrhage symptoms or the time from last normal to detection is not more than 72 hours. 4. patients with glasgow coma scale (gcs) score ≥6 and \< 12. 5. before the onset of the disease, function was independent and mrs score\<1. 6. able and willing to sign written informed consent and comply with the requirements of the research protocol. exclusion criteria: 1. multifocal cerebral hemorrhage, brain stem hemorrhage, or ventricular hemorrhage. 2. secondary cerebral hemorrhage caused by aneurysm, brain tumor, arteriovenous malformation, thrombocytopenia, coagulation disorder, traumatic brain injury, etc. 3. patients who require hematoma removal surgery or other emergency surgical interventions (such as decompressive craniectomy), or who are critically ill and close to death. 4. patients who interfere with drug use due to nausea or vomiting. 5. combined with the following conditions that preclude participation in the study due to other systemic diseases: severe hepatic or renal impairment, atrial fibrillation or tachycardia, pulmonary infection, severe urinary tract infection, severe urinary tract obstruction, medically uncontrolled hypertension (systolic blood pressure ≥180mmhg or diastolic blood pressure ≥110mmhg), pregnant and lactating women, and a history of malignant tumors within 5 years.
hero graft compared to permanent catheters for end stage renal disease (esrd) patients receiving hemodialysis

Conditions: End Stage Renal Disease (ESRD)

Summary: the main objective of this research study was to compare the following outcomes between patients with a hemodialysis reliable outflow (hero) graft and patients with a cuffed catheter for dialysis access over one year: quality of life and incidence of bacteremia, vascular interventions, hospitalizations, and death.

all eligible participants who provided informed consent were included in the study. participants who refused hero graft implantation, or did not have the hero graft implanted for any other reason, were followed in the control group. several patients did not receive the hero graft due to anatomical challenges and failure to complete both steps of the two-stage implant procedure. all consented participants who had an implanted hero graft were followed in the study group. all participants were followed until the study end, withdrawal, loss to follow-up, or death. the analysis included only hero graft patients and control patients who were not lost to follow-up; patients who were lost to follow-up, before data collection, were excluded from analysis. after obtaining institutional review board (irb) approval, baseline demographic and clinical data was collected. following surgery, implant procedure data was collected on study participants who received hero grafts. hero grafts were placed using a 2-step process with initial placement of the eptfe portion, followed by completion of the graft by placement of the venous outflow component. following enrollment, outcomes of interest were collected at follow-up visits scheduled weekly for 4 weeks, bi-weekly for 3 months, and monthly to 1 year, for a total of 18 follow-up visits. study coordinators documented post-operative complications, incidence of thrombosis, hospitalizations, infection incidents, and deaths at each follow-up. quality of life data were also collected from all participants using the rand corporation's short form (36) (sf-36) health survey. this survey was completed at enrollment and again at 3 months, 6 months, and 12 months.

Eligibility criteria:
inclusion criteria: * esrd patients requiring hemodialysis * age ≥ 18 years old * able to give informed consent * able to participate in quality of life survey * all patients who are not candidate for arteriovenous fistula (avf) or arteriovenous graft (avg) * life expectancy 2 years or greater * willing and able to participate with follow-up examinations exclusion criteria: * pregnant or breastfeeding females * disorder that compromises the ability to give informed consent and/or comply with the study procedures * any medical condition that in the opinion of the investigator may pose a safety risk to a subject in the study or which may interfere with the study participation

Keywords: dialysis hero graft catheter chronic renal failure end stage renal disease renal insufficiency